Supplementary Figure 1 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma by Erik Ladomersky (15027230)

Supplementary Figure 3 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma by Erik Ladomersky (15027230)

Supplementary Figure 4 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma by Erik Ladomersky (15027230)

Decreasing Nitrogen Fertilizer Input Had Little Effect on Microbial Communities in Three Types of Soils - Fig 2 by Hailing Yu (3176067)

Rapamycin decreases neoblast proliferation and increases the survival rate in <i>Smed-smg-1</i> RNAi animals. by Cristina González-Estévez (175872)

<i>NHD13/Rag1</i>KO mice have decreased survival and an increased incidence of leukemia. by Sheryl M. Gough (323307)

“…<p>(A) Survival is dramatically reduced in the <i>NHD13</i> mice and further decreased in the <i>NHD13/Rag1</i>KO cohort (Mantel Cox test p = 0.01); median lifespan of the <i>NHD13/Rag1</i>KO mice is two months less than the NHD13 cohort. …”

<i>l</i>-THP decreased myocardial infarct size in myocardial I/R (MI/R) rats. by Yi Han (194901)

Administration of anti-CD25 antibody decreases the early and late organ fungal burdens of resistant and susceptible mice. by Maíra Felonato (296591)

Retinoic acid decreases ATF-2 phosphorylation and sensitizes melanoma cells to taxol-mediated growth inhibition-3 by Ying Huang (53474)

The inactivation of the acetyl-CoA acyltransferase 1 enzyme by the novel putative miRNA Oeu124369 leads to a decrease in Acetyl-CoA production and additionally, the deactivation of... by Mohammad Hossein Pakdel (19837942)

Expression of structural proteins and calcium pump in the heart after trauma. by Miriam Kalbitz (3150195)

“…<p>Altered expression of z-disc proteins and calcium pump SERCA after blunt chest trauma in the heart. A. Decrease in desmin expression 24 h and 5 d after blunt chest trauma compared to sham procedure. …”

Deletion of <i>Ulk1</i> inhibits neointima formation by enhancing KAT2A/GCN5-mediated acetylation of TUBA/α-tubulin <i>in vivo</i> by Changhan Ouyang (3637546)

“…Finally, local transfection of <i>Kat2a</i> siRNA decreased TUBA acetylation and prevented the attenuation of vascular injury-induced neointima formation in <i>ulk1</i> KO mice. …”

Probing Field Cancerization in the Gastrointestinal Tract Using a Hybrid Raman and Partial Wave Spectroscopy Microscope by Elena Kriukova (21524544)

“…In the normal tissue of L2-IL1B mice, we demonstrate a statistically significant increase (<i>p</i> < 0.001) in Raman band intensities associated with free amino acids and a decrease in bands associated with lipids (<i>p</i> < 0.005) and carotenoids (<i>p</i> < 0.001) compared to healthy controls. …”

p.Arg554Leu-<i>BRAP</i> variant triggered decreasing apoptotic cells in hPASMCs. by Ayako Chida-Nagai (6281843)

Knock-down of endogenous p66α or p66β decreases MBD2-mediated repression by Marc Brackertz (27647)

NG2 knockdown in GBM xenografts increased vascular reabsorption, decreased plasma volume and normalized tumour vasculature. by Jian Wang (5901)

Identification and validation of <i>Ctsz</i> as the lead candidate gene underlying <i>Tip5.</i> by Rachel K. Meade (22216529)

Mitochondrial dysfunction in sIBM patients. by Yoshitsugu Oikawa (9721356)

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”